Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Abd-Elsalam, 2020
 
NCT04353336
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
97/97 inconclusive
    ARCHAIC -hydroxychloroquine, 2020
     
    NL8490
    RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
    9/6 inconclusive
      CCAP-1, 2020
       
      NCT04345289
      RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
      -/- inconclusive
        Chen, 2020
         
        NCT04384380
        RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
        21/12 inconclusive
          Duke university HCQ, 2020
           
          NCT04335552
          RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
          4/2 no results
            discontinued, found in Axfors et al. meta-analysis
            HAHPS, 2020
             
            NCT04329832
            RCThydroxychloroquineazithromycinCOVID 19 hospitalizedsome concern
            42/43 inconclusive
            • inconclusive 7 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
            HYCOVID, 2020
             
            NCT04325893
            RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
            124/123 inconclusive
            • inconclusive 12 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
            NO COVID-19 (Lyngbakken), 2020
             
            NCT04316377
            RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
            27/26 inconclusive
              OAHU-COVID19, 2020
               
              NCT04345692
              RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
              10/6 inconclusive
                ORCHID, 2020
                 
                NCT04332991
                RCThydroxychloroquineplaceboCOVID 19 hospitalizedlow
                242/237 inconclusive
                • inconclusive 2 % increase in clinical improvement (PE) with a high degree of certainty due to low risk of bias
                PROTECT B, 2020
                 
                NCT04338698
                RCThydroxychloroquineoseltamivirCOVID 19 hospitalizedNA
                -/- inconclusive
                  RECOVERY, 2020
                   
                  NCT04381936
                  RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
                  1561/3155 safety concern
                  • inconclusive 9 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                  • statistically significant 14 % increase in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
                  Sekhavati, 2020 RCThydroxychloroquinelopinavir/ritonavirCOVID 19 hospitalizedsome concern
                  56/55 inconclusive
                  • inconclusive 51 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
                  Sekhavati, 2020 RCThydroxychloroquinehydroxychloroquineCOVID 19 hospitalizedsome concern
                  56/55 inconclusive
                  • inconclusive 51 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
                  SOLIDARITY (WHO study) HCQ, 2020
                   
                  NCT04315948
                  RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
                  947/906 inconclusive
                  • inconclusive 19 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                  Tang, 2020
                   
                  ChiCTR2000029868
                  RCThydroxychloroquinestandard of careCOVID 19 hospitalizedhigh
                  75/75 safety concern
                  • statistically significant 3.5-fold increase in adverse events but with a low degree of certainty due to high risk of bias
                  TEACH, 2020
                   
                  NCT04369742
                  RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
                  67/61 inconclusive
                  • inconclusive 80 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
                  • inconclusive 16 % increase in adverse events (PE) with a moderate degree of certainty due to some concern in risk of bias
                  Arshad (HCQ), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                  1202/409 suggested
                  • suggested 66 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
                  Belgian Collaborative Group on COVID-19, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
                  4542/3533 suggested
                  • suggested 32 % decrease in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
                  Geleris, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
                  811/565 inconclusive
                    Magagnoli (HC), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
                    97/158 safety concern
                    • safety concern with statistically significant 1.6-fold increase in deaths,deaths (time to event analysis only)
                    Novales, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                    123/43 suggested
                    • suggested 93 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
                    Paccoud, 2020 OBShydroxychloroquinestandard of careCOVID 19 hospitalizedserious
                    38/46 inconclusive
                      Sbidian (HCQ alone), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                      623/3792 safety concern
                      • statistically significant 25 % increase in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
                      Singh, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                      -/- inconclusive

                        COVID 19 all comers meta-analysis

                        ChiCTR2000030054-HCQ (Chen), 2020
                         
                        ChiCTR2000030054
                        RCThydroxychloroquinestandard of careCOVID 19 all comershigh
                        18/12 inconclusive
                          Gautret et al., 2020 NRahydroxychloroquinecontrolCOVID 19 all comersserious
                          20/16 suggested
                          • suggested 15.3-fold increase in PCR-negative conversion (PE) but with a low degree of certainty due to high risk of bias
                          a viral load reduction/disappearance is claimed but the numerous methological limits preclude any strong conclusion

                          COVID-19 mild to moderate meta-analysis

                          Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020
                           
                          NCT04322123
                          RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
                          221/227 safety concern
                          • statistically significant 74 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
                          HC-nCoV (Shanghai), 2020
                           
                          NCT04261517
                          RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
                          15/15 inconclusive
                            NCT04333654, 2020
                             
                            NCT04333654
                            RCThydroxychloroquinestandard of careCOVID-19 mild to moderateNA
                            -/- inconclusive
                              Zhaowei Chen, 2020
                               
                              ChiCTR2000029559
                              RCThydroxychloroquinecontrolCOVID-19 mild to moderatehigh
                              31/31 inconclusive
                                Zhaowei Chen, 2020
                                 
                                ChiCTR2000029559
                                RCThydroxychloroquinestandard of careCOVID-19 mild to moderatehigh
                                31/31 suggested
                                • suggested 2.4-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias
                                • suggested 2.4-fold increase in radiologic improvement (7-day) but with a low degree of certainty due to high risk of bias
                                Min, 2020 OBShydroxychloroquinecontrolCOVID-19 mild to moderateNA
                                20/20 inconclusive

                                  COVID-19 severe or critically meta-analysis

                                  HYDRA, 2020
                                   
                                  NCT04315896
                                  RCThydroxychloroquineplaceboCOVID-19 severe or criticallyNA
                                  75/77 inconclusive
                                  • inconclusive 1 % decrease in deaths (PE)
                                  REMAP-CAP-HCQ, 2020
                                   
                                  NCT02735707
                                  RCThydroxychloroquinestandard of careCOVID-19 severe or criticallyNA
                                  61/81 inconclusive
                                  • inconclusive 4 % increase in deaths (PE)
                                  REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.multi-arm study
                                  Mahevas, 2020 OBShydroxychloroquinestandard of careCOVID-19 severe or criticallyserious
                                  84/97 inconclusive
                                    Yu, 2020 OBShydroxychloroquinecontrolCOVID-19 severe or criticallycritical
                                    48/520 suggested
                                    • suggested 68 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias

                                    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                                    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).